CSL has unified its business units together under a single global brand, the century-old Australian biotech announced.
As part of the rebrand, CSL Behring, which delivers therapies for rare and serious diseases, will maintain its current identity, as will CSL Plasma, the company’s plasma collection business. Seqirus, a provider of influenza vaccines, will become CSL Seqirus, while recently acquired Vifor Pharma, which specializes in therapies for kidney disease, will be known as CSL Vifor.
CSL is in the process of formally changing the name for Seqirus and plans to refresh the names of the Vifor Pharma entities “in due time,” the company said.
The “timing was right” for the rebrand, said CEO and managing director Paul Perreault in a video detailing the visual and structural changes.
The organization is also coming together “under one CSL” in terms of its culture and values — patient focus, innovation, integrity, collaboration and superior performance — and has refreshed the descriptors of each of these values, Perreault added.
